| # | Title | Journal | Year | Citations |
|---|
| 1 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Lancet Oncology, The | 2010 | 1,915 |
| 2 | Cervical cancer | Lancet, The | 2019 | 1,367 |
| 3 | Development of PI3K inhibitors: lessons learned from early clinical trials | Nature Reviews Clinical Oncology | 2013 | 694 |
| 4 | First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement | Cancer Discovery | 2013 | 618 |
| 5 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer | Journal of Clinical Oncology | 2009 | 582 |
| 6 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer | JAMA Oncology | 2017 | 555 |
| 7 | Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology | 2008 | 519 |
| 8 | The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus | Oncologist | 2012 | 453 |
| 9 | ESMO-Magnitude of Clinical Benefit Scale version 1.1 | Annals of Oncology | 2017 | 451 |
| 10 | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Oncogene | 2009 | 385 |
| 11 | Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Lancet Oncology, The | 2017 | 377 |
| 12 | Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors | Molecular Cancer Therapeutics | 2014 | 375 |
| 13 | Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2007 | 306 |
| 14 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Cancer Discovery | 2019 | 278 |
| 15 | Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs | Oncotarget | 2010 | 278 |
| 16 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 239 |
| 17 | Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC | JAMA Oncology | 2019 | 235 |
| 18 | Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma | JAMA Oncology | 2017 | 233 |
| 19 | BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives | Annals of Oncology | 2017 | 227 |
| 20 | Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials | Oncologist | 2013 | 210 |
| 21 | BRCA in breast cancer: ESMO Clinical Practice Guidelines | Annals of Oncology | 2011 | 174 |
| 22 | Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies | Annals of Oncology | 2017 | 174 |
| 23 | Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC) | Clinical Lung Cancer | 2011 | 171 |
| 24 | Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy | JCI Insight | 2018 | 168 |
| 25 | The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 | Nature Clinical Practice Oncology | 2008 | 153 |
| 26 | Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer | Cancer Discovery | 2020 | 151 |
| 27 | Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. | Journal of Clinical Oncology | 2020 | 150 |
| 28 | Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma | American Journal of Clinical Oncology: Cancer Clinical Trials | 2018 | 145 |
| 29 | Management of breast cancer with targeted agents: importance of heterogenicity | Nature Reviews Clinical Oncology | 2010 | 143 |
| 30 | The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma | Journal of Thoracic Oncology | 2016 | 139 |
| 31 | Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | 2015 | 138 |
| 32 | Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Annals of Oncology | 2019 | 136 |
| 33 | Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors | JNCI Cancer Spectrum | 2020 | 126 |
| 34 | Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors | Annals of Oncology | 2012 | 125 |
| 35 | The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. Behandlung der Hautreaktionen bei EGFR-spezifischer Tumortherapie (Epidermaler Wachstumsfaktor Rezeptor) | JDDG - Journal of the German Society of Dermatology | 2005 | 121 |
| 36 | Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment | Cancer Treatment Reviews | 2009 | 120 |
| 37 | Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs | Oncologist | 2011 | 117 |
| 38 | Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study | Journal of Clinical Oncology | 2010 | 113 |
| 39 | Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I | Annals of Oncology | 2021 | 105 |
| 40 | Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial | Annals of Oncology | 2018 | 101 |
| 41 | The expanding role of immunotherapy | Cancer Treatment Reviews | 2017 | 100 |
| 42 | Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses | JAMA Oncology | 2018 | 98 |
| 43 | Sorafenib in metastatic thyroid cancer | Endocrine-Related Cancer | 2012 | 96 |
| 44 | FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements | Future Oncology | 2020 | 96 |
| 45 | A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect | Nature Communications | 2014 | 94 |
| 46 | Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab | Annals of Oncology | 2017 | 93 |
| 47 | Targeting FGFR pathway in breast cancer | Breast | 2018 | 89 |
| 48 | New clinical trial designs in the era of precision medicine | Molecular Oncology | 2019 | 89 |
| 49 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 | ESMO Open | 2016 | 82 |
| 50 | Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer | Annals of Oncology | 2020 | 80 |
